Synthesis and characterization of the trans- and cis-isomers of N-acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine and their attempted detection in human urine

• Published in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 1246; p. 124294
• Main Authors: Yang, Fei, Cao, Yi-Yi, Xi, Jing, Luan, Yang, Li, Na, Dong, Xin, Zhang, Xin-Yu
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2024
• Subjects: Acetylcysteine - analogs & derivatives; Acetylcysteine - chemistry; Acetylcysteine - urine; Biomarkers - urine; Biomonitoring; Butadiene; Butadienes - chemistry; Butadienes - urine; Chromatography, Liquid - methods; Cysteine - analogs & derivatives; Cysteine - chemistry; Cysteine - urine; Human urine; Humans; Isomerism; Limit of Detection; Male; N-acetyl-L-cysteine conjugates; Reproducibility of Results; Tandem Mass Spectrometry - methods; Urinary biomarkers; bis-BDMA; PATH; Biomonitoring; BD; bis-N7G-BD; EB-GII; MHBMA3; MHBMA; HEAL; MRM; MHBMA1; NZ; COSY; DHBMA; MHBMA2; Butadiene; E-CBol; Human urine; 4HBeMA; EB; NC1; LOD; Z-CBol; THBMA; LOQ; NAC; NMR; GCS; HMQC; NE; CITU; NHANES; N-acetyl-L-cysteine conjugates; Urinary biomarkers; NCS
• ISSN: 1570-0232; 1873-376X; 1873-376X
• DOI: 10.1016/j.jchromb.2024.124294

•N-acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine is a biomarker of 1,3-butadiene (BD).•It is called MHBMA3 and a contradiction as to its presence in human urine exists.•MHBMA3 in most studies is the trans-isomer (NE) and we developed a LC-MS/MS method.•No MHBMA3 but an interfering peak was detected in urine of BD-exposed subjects.•The peak was susceptible to coelution with NE and may have been misidentified as NE. 1,3-Butadiene (BD) is a carcinogenic air pollutant. N-acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine (MHBMA3 or 4HBeMA), an urinary BD metabolite with unspecified configuration, is considered the most sensitive BD biomarker and has been used in routine biomonitoring since 2012. However, two issues remain unaddressed: why its concentrations are unusually high relative to other urinary BD biomarkers and why some authors reported no detection of the biomarker whereas other authors readily quantitated it. To address the issues, we synthesized and structurally characterized the authentic trans- and cis-isomers of MHBMA3 (designated NE and NZ, respectively), developed an isotope-dilution LC-MS/MS method for their quantification, and examined 67 urine samples from barbecue restaurant personnel (n = 47) and hotel administrative staff (n = 20). The restaurant personnel were exposed to barbecue fumes, which contain relatively high concentrations of BD. The results showed that NE and NZ had highly similar NMR spectra, and were difficult to be well separated chromatographically. The NMR data showed that the MHBMA3 isomer investigated in most previous studies was NE. We did not detect NE and NZ in any samples; however, an interfering peak with varying heights was observed in most samples. Notably, under the chromatographic conditions used in the literature, the peak exhibited indistinguishable retention time from that of NE. Thus, it is highly likely that the interfering peak has been mis-identified as NE in previous studies, providing a reasonable explanation for the high MHBMA3 concentration in urine. The contradiction in the presence of MHBMA3 in urine was also caused by the mis-identification, because the researchers who reported the absence of MHBMA3 were actually detecting NZ. Thus, we clarified the confusion on MHBMA3 in previous studies through correctly identifying the two MHBMA3 isomers. The presence of NE and NZ in human urine warrants further investigations.